AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Eye on Central Otago as new West African gold belt
Markets

Eye on Central Otago as new West African gold belt

KO Gold sees similarities between Africa’s Berimian Greenstone region and Central Otago.

Investors cream $214m from Fonterra Mainland sale
Primary Sector

Investors cream $214m from Fonterra Mainland sale

From “dismal” returns to a windfall and rocketing unit price. But what's next?

NZ sharemarket starts new week up 0.2%
Markets Market Close

NZ sharemarket starts new week up 0.2%

The S&P/NZX 50 Index closed at 13,499.04, up 34.58 points or 0.26%.

Graham Skellern 17 Nov 2025
The Warehouse CEO Mark Stirton unveils cost reset amid margin pressure
Retail

The Warehouse CEO Mark Stirton unveils cost reset amid margin pressure

Continued margin pressure and an unsustainable cost base have led The Warehouse Group to implement a comprehensive cost reset programme, something which could see head office roles slashed to save costs.Chief executive Mark Stirton said the group’s shareholders expect decisive ac...

Staff reporters 17 Nov 2025